secwatch.observer — SEC 8-K summary
======================================

Issuer:     Entrada Therapeutics, Inc. (TRDA)
CIK:        0001689375
Form:       8-K
Filed at:   2025-06-03T23:59:59+00:00
Accession:  0001689375-25-000027
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Entrada Therapeutics appoints Maha Radhakrishnan, M.D. to board effective June 1, 2025
--------------------------------------------------------------------------------

- Maha Radhakrishnan, M.D. appointed as Class III director; board expanded from 6 to 7 members.
- Also appointed to Audit Committee, replacing Kush Parmar, M.D., Ph.D.; Parmar remains chairman.
- Current Executive Partner at Sofinnova Investments; former CMO of Biogen (2019-2024).
- Initial equity award: option to purchase 38,000 shares vesting over 3 years; annual cash fees of $40,000 + $9,000 Audit Committee retainer.
- Appointment takes effect June 1, 2025; serves until 2027 annual meeting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1689375/000168937525000027/0001689375-25-000027-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1689375/000168937525000027/trda-20250530.htm
  HTML page:      https://secwatch.observer/filing/0001689375-25-000027

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer